SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
P/E ratio for SI-BONE, Inc. (SIBN)
P/E ratio as of 2023: -18.61
According to SI-BONE, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -18.61. At the end of 2022 the company had a P/E ratio of -7.39.
P/E ratio history for SI-BONE, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -18.61 |
| 2022 | -7.39 |
| 2021 | -12.24 |
| 2020 | -17.90 |
| 2019 | -12.48 |
| 2018 | -19.03 |
| 2017 | -12.08 |
| 2016 | -15.08 |
| 2015 | -17.15 |
| 2014 | -1.93 |
| 2013 | -7.46 |
| 2012 | -3.48 |